Skip to content

Stock·NYSE·Healthcare

Pfizer Inc. (PFE)

$27.40 -0.14 (-0.51%)
At close: Nov 20, 4:00 PM EST
Sell
40 / 100
CleaRank Financial AI scorei
Market cap
$156.18B
P/E
39.14
Dividend yield
6.28%
Street target
$30.00median of 28 analysts
52-week range
$23.62 $31.44

What moved Pfizer Inc. (PFE)

Updated . Market figures as of November 20, 2026.

Was it the market or the company?

On November 20, 2026, PFE fell 0.51%. The same day the S&P 500 (SPY) fell 3.64%, the Nasdaq 100 (QQQ) fell 5.67% and the health care sector (XLV) fell 0.12%.

The move was in line with the market. PFE's one-year beta to SPY is 0.28, so SPY's -3.64% would on average have meant -1.01% for PFE, close to what it did (0.5 percentage points less).

Over the last 20 sessions PFE is down 8.76% against -9.23% for SPY, 0.5 percentage points ahead of it.

The wider market on November 20, 2026: CNBC reported that the sell-off's breaking point came with Anthropic's initial public offering and heavier selling in Nvidia, which it named as the first of five forces behind the drop. (CNBC, November 20, 2026)

Moves to November 20, 2026, side by side
That day 5 sessions 20 sessions
PFE -0.51% -5.16% -8.76%
S&P 500 (SPY) -3.64% -8.56% -9.23%
Nasdaq 100 (QQQ) -5.67% -10.51% -13.62%
Health care sector (XLV) -0.12% -6.15% -1.14%

Calculated by CleaRank from daily closes. Beta is measured on the last year of daily returns against SPY. A description of what happened, not a forecast.

What changed since November 19, 2026

  • CleaRank score: 41/100 on November 19, 2026, 40/100 on November 20, 2026. The rating went from Hold to Sell.
01

PFE stock today, November 22, 2026: price, news and analyst targets

As of November 20, 2026, Pfizer Inc. (PFE) trades at $27.40. Wall Street's median 12-month price target is $30.00 across 28 analysts, 9.5% above the price. CleaRank rates it Sell with a score of 40/100.

Pfizer's stock is trading at $27.40, sitting between its 200-day average of $27.03 and its 50-day average of $28.82, and the CleaRank rating moved to Sell on November 20, 2026 as the score slipped to 40/100 from 41/100 the day before. The score had stood at 56/100 on November 16, 2026, so the drop over those days has been steady rather than sudden. The pressure comes mainly from momentum and valuation, with the stock below its shorter-term averages and trading at a premium to the sector on earnings. Analysts remain more constructive than the rating, with a median 12-month target of $30.00 and a consensus of Hold.

Why the rating moved to Sell

The CleaRank score has fallen across several sessions, from 56/100 on November 16, 2026 to 49/100 on November 17, 2026, to 43/100 on November 18, 2026, to 41/100 on November 19, 2026, and to 40/100 on November 20, 2026. The rating went from Hold to Sell on the last of those dates. The largest drags are momentum and valuation. The 14-day RSI is 32.5, in the bearish zone, and the MACD line is negative. The stock trades at a trailing P/E of 39.14, a premium to peers against a sector median of 31.9. The price-to-sales ratio of 2.45 sits 27.9% below the sector median of 3.4, so the premium is tied to earnings rather than sales.

Trend and the moving averages

The trend reading is mixed. The stock is 1.38% above its 200-day average but 4.93% below its 50-day average, and the 50-day average is 6.64% above the 200-day average. Over the past month the stock fell 8.21%, and over the past week it fell 5.16%. Over six months it is up 5.79% and over the year it is up 12.30%, so the longer-term direction remains positive even as the short-term picture has weakened.

Business and earnings backdrop

Revenue grew 2.60% in the latest quarter compared with the same quarter a year earlier, which is slower than the sector median growth of 8.1%. Net profit margin is 6.3% against an operating margin of 29.07%, and return on equity of 4.47% is below the sector median of 7.3%. The debt-to-equity ratio is 0.71. Analysts are more positive than the rating: of 28 analysts, 9 rate the stock buy or strong buy, 17 hold it and 2 sell it, and the median 12-month target is $30.00.

Dividend and insider activity

The trailing dividend yield is 6.28% on an annual dividend of $1.72 per share, a yield that is high for the sector and that supports the stock's appeal to income investors. Over the last 18 months insiders bought $3.0M of stock across three open-market purchases and sold $135K across two sales. Insider sales are often planned in advance or made to cover tax on vesting shares, so the open-market buying is the more telling signal of the two.

CleaRank score 40/100 (Sell). 9 of 18 checks pass: trend 2 of 4, momentum 1 of 3, valuation and quality 3 of 4, analysts 1 of 3, track record 2 of 4.

About Pfizer

Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines for people worldwide. Its current portfolio spans oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and hospital-based care, supported by a broad commercial network that serves physicians, hospitals, pharmacies, governments, and healthcare systems. Pfizer also maintains a consumer health presence through established over-the-counter and wellness products in select markets.

02

PFE stock news

  • Freedom Broker keeps Buy view

    ·Freedom Broker

    Freedom Broker kept its Buy rating on November 7, 2026, one of two Buy reiterations from that firm in consecutive days. Repeated Buy ratings from a broker add to the analyst support that sits behind the $30.00 median target.

  • Second Freedom Broker Buy reiteration

    ·Freedom Broker

    On November 6, 2026 Freedom Broker again kept its Buy rating on the stock. A second reiteration in two days shows the firm still sees upside from the current price.

  • Guggenheim keeps Buy rating

    ·Guggenheim

    Guggenheim kept its Buy rating on November 5, 2026. The stock has a number of Buy ratings, but the broad split of 9 buy ratings against 17 holds shows that support is far from unanimous.

  • UBS holds Neutral stance

    ·UBS

    UBS kept its Neutral rating on November 4, 2026. A neutral stance from a large broker matches the overall Hold consensus and gives no clear push in either direction.

  • Citigroup holds Neutral stance

    ·Citigroup

    Citigroup kept its Neutral rating on November 4, 2026, alongside UBS. Two large brokers holding neutral views on the same day keeps the consensus anchored at Hold.

03

PFE price target 2026

The base case for the coming months is a stock that stays range-bound between its 200-day average and its 50-day average while the momentum readings stay weak. For the picture to improve, the price needs to reclaim the 50-day average at $28.82 and hold above the 20-day average, which would ease the bearish pressure on the trend factor. Analysts' median target of $30.00 sits above the price, and the highest target of $37.00 implies room if the company's revenue growth, which grew 2.60% year on year, begins to close the gap to the sector median of 8.1%. The downside case is a close below the 200-day average at $27.03, which would bring the 52-week low of $23.62 into view. Given the premium P/E of 39.14 against a sector median of 31.9, any slowdown in earnings would likely weigh on the valuation further. Recent insider buying of $3.0M across three purchases is a point in the stock's favour, though insider sales are often planned in advance and carry less weight.

Analyst targets and ratings

12-month price targets

Low $25.00 Median $30.00 (+9.5%) High $37.00

Ratings

Buy 9 Hold 17 Sell 2 3 months ago: 10 of 28 buy

Recent rating actions

Recent analyst rating actions on PFE
Date Firm Action Rating
Nov 7, 2026 Freedom Broker Maintains Buy
Nov 6, 2026 Freedom Broker Maintains Buy
Nov 5, 2026 Guggenheim Maintains Buy
Nov 4, 2026 UBS Maintains Neutral
Nov 4, 2026 Scotiabank Maintains Sector Outperform
Nov 4, 2026 Citigroup Maintains Neutral
04

PFE support and resistance levels

Support sits first at the 200-day simple moving average of $27.03, which the price is just above and which is the level a fall would meet first. Below that, the 52-week low of $23.62 marks the bottom of the stock's one-year range and the next level a sustained decline would reach. Resistance starts at the 50-day simple moving average of $28.82, which the stock fell back below on November 17, 2026. Just above it, the 20-day exponential moving average of $28.88 is the next barrier, and the 52-week high of $31.44 is the final level a rally would need to clear.

PFE support and resistance levels
Level What it is Price From the price
Resistance 3 52-week high $31.44 +14.7%
Resistance 2 20-day exponential average $28.88 +5.4%
Resistance 1 50-day moving average $28.82 +5.2%
Price November 20, 2026 $27.40
Support 1 200-day moving average $27.03 -1.4%
Support 2 52-week low $23.62 -13.8%

Technical indicators

Technical rating Bearish 1 of 4 signals bullish
  • RSI Bearish
  • SMA cross Bullish
  • Price vs SMA Bearish
  • MACD Bearish
Momentum Bearish
32.514-day RSI
Oversold <30 Neutral Overbought >70
MACD (12, 26) -0.333 Bearish
Trend Golden cross
-4.9%price against the 50-day average
200-day $27.03 50-day $28.82 Price $27.40
Price against the 200-day +1.4% Bullish

PFE technical analysis in depth

Volatility, momentum, trend strength and the price levels that matter for PFE, calculated by CleaRank from daily bars to November 20, 2026.

Volatility

On the 20-day Bollinger Bands (2 standard deviations) the bands run from $27.48 to $31.15 around a middle of $29.32, and PFE's close of $27.40 sits below the lower band, a stretched reading.

Band width is 12.5% of the price, in the middle of its range over the last 120 sessions.

The 14-day average true range is $0.6728, or 2.5% of the price: a typical day's swing from high to low. A stop placed 1.5 ATR away would sit about 3.7% from the close.

Momentum and volume

The 14-day stochastic reads 1 (signal line 2): the close is near the bottom of its two-week range, an oversold zone.

The MACD line (12, 26) is -0.333 against a signal line (9) of -0.022, so the histogram is negative: momentum is weakening relative to its recent average. The MACD line crossed below its signal line 11 sessions ago.

Volume in the latest session was 1.0 times its 20-day average.

Trend strength

The 14-day ADX is 19, under 20: no strong trend in either direction, though sellers have the edge (+DI 20, -DI 26).

On the weekly chart the 10-week average ($28.82) is above the 40-week average ($27.00), a rising longer-term trend, and the weekly RSI is 49.

Key levels

The nearest resistance from the price history is $27.55 (+0.5%): the price turned here 6 times, most recently on October 5, 2026.

The nearest support is $26.52 (-3.2%): the price turned here 8 times, most recently on June 12, 2026.

The largest swing of the last 120 sessions ran up from $23.62 (June 25, 2026) to $31.44 (November 5, 2026); the nearest Fibonacci retracement to the price is the 50.0% level at $27.53.

Classic pivot points for the next session, from November 20, 2026: pivot $27.62, resistance $27.89 and $28.38, support $27.13 and $26.86.

PFE key price levels
Level Price From the price What it is
Upper Bollinger Band $31.15 +13.7% 20-day average + 2 standard deviations
Fibonacci 23.6% $29.59 +8.0% retracement of the rise from $23.62 to $31.44
Resistance (swing high) $29.03 +6.0% the price turned here 4 times, most recently on October 28, 2026
Fibonacci 38.2% $28.45 +3.8% retracement of the rise from $23.62 to $31.44
Pivot R2 (classic) $28.38 +3.6% next-session level
Resistance (swing high) $28.14 +2.7% the price turned here 3 times, most recently on November 6, 2026
Pivot R1 (Fibonacci) $27.91 +1.9% 38.2% of the last range above the pivot
Pivot R1 (classic) $27.89 +1.8% next-session level
Pivot point $27.62 +0.8% average of the last high, low and close
Resistance (swing high) $27.55 +0.5% the price turned here 6 times, most recently on October 5, 2026
Fibonacci 50.0% $27.53 +0.5% retracement of the rise from $23.62 to $31.44
Lower Bollinger Band $27.48 +0.3% 20-day average - 2 standard deviations
Price $27.40 close, November 20, 2026
Pivot S1 (Fibonacci) $27.33 -0.3% 38.2% of the last range below the pivot
Pivot S1 (classic) $27.13 -1.0% next-session level
Pivot S2 (classic) $26.86 -2.0% next-session level
Fibonacci 61.8% $26.61 -2.9% retracement of the rise from $23.62 to $31.44
Support (swing low) $26.52 -3.2% the price turned here 8 times, most recently on June 12, 2026
Support (swing low) $25.55 -6.8% the price turned here 4 times, most recently on July 17, 2026
Fibonacci 78.6% $25.29 -7.7% retracement of the rise from $23.62 to $31.44
Support (swing low) $24.84 -9.3% the price turned here 7 times, most recently on July 27, 2026

Swing levels are highs and lows the price turned at (the extreme of the five sessions either side), merged when they sit within 1.2 average true ranges of each other. Bollinger Bands (20, 2), ATR (14, Wilder), stochastic (14, 3), MACD (12, 26, 9), ADX (14, Wilder). Readings describe the chart; they are not a forecast.

05

PFE stock price and trading

PFE share price

Start $24.40 Nov 20, 2025
Latest close $27.40 Nov 20, 2026
High $30.79 Nov 4, 2026
Low $23.67 Jun 25, 2026
06

PFE fundamentals and valuation

Key statistics

Market Cap
156.18B
P/E Ratio
39.14
EPS (TTM)
$0.70
Dividend Yield
6.28%
52 Week High
31.44
52 Week Low
23.62

PFE against the Healthcare sector

P/E ratio 23% above the median
PFE
39.1x
Sector median
31.9x
P/S ratio 28% below the median
PFE
2.5x
Sector median
3.4x
Revenue growth, year on year 5.5 points below the median
PFE
2.6%
Sector median
8.1%
Return on equity 2.8 points below the median
PFE
4.5%
Sector median
7.3%

Price to earnings vs sector: PFE trades at a significant premium to sector peers (+23% against the sector median P/E). Investors are paying more for each dollar of earnings than for the typical stock in the sector.

Return vs XLV: Since Jun 11, 2025, PFE has gained 11.9% against a gain of 30.6% for XLV.

Performance against XLV

PFE XLV

Revenue and earnings

Revenue, 12 months
$63.6B
Net income, 12 months
$4.0B
Net margin
6.3%
Revenue growth
+2.6%
Q2 '26, year on year
FY202127% marginFY202231% marginFY20234% marginFY202413% marginFY202512% margin
Revenue Net income

Revenue growth: Revenue fell 1.6% in FY2025 to $62.6B, from $63.6B a year earlier.

Profit margin: The net margin was 12.5% in FY2025, down from 12.7% the year before.

Profitable: PFE earned $7.8B in FY2025.

07

PFE price history and drawdowns

Risk profile

Beta
0.30
against the S&P 500; 1 moves with the market
Daily volatility
1.50%
30-day standard deviation
52-week range
$27.40
$23.62 48% of the way up $31.44

Worst falls and recoveries

Worst fall, last 10 years
-57.8%
December 2021 to April 2025
Recovery
Not yet
still 39.9% below the December 2021 peak
From the 10-year high
-39.9%
peak with dividends reinvested, December 2021
1-year holds that gained
57%
of every 1-year window

Growth of $10,000

PFE today
$14,444
from $10,000 in December 2016, dividends reinvested
S&P 500 today
$36,764
the same $10,000 in SPY, dividends reinvested
Behind the index by
$22,320
0.4x the index result
Total change
+44%
1.4x the starting amount
PFE S&P 500 (SPY)

Against the market: PFE trailed the S&P 500 over this period: $14,444 against $36,764.

A $10,000 investment in PFE in December 2016 would be worth about $14,444 today with dividends reinvested, compared with about $36,764 for the same investment in the S&P 500 benchmark (also with dividends reinvested).

08

PFE stock price prediction 2030

PFE Stock Price Prediction 2030: Simulated Scenarios

Price today
$27.40
Base case, 2030
$30.44
1.1x over 4 years
Range, 2030
$16.41 to $56.47
10th to 90th percentile

CleaRank's simulation projects a price near $30.44 for PFE by 2030 in the base case, from $27.40 today (1.1x over 4 years). The 10th-percentile path ends near $16.41. These are outcomes of a Monte Carlo simulation run on PFE's historical return distribution, not price targets, and they assume no dividends are reinvested.

PFE simulated price paths by year
Year 10th percentile Base case 90th percentile range base today
2027 $20.65 $28.13 $38.31
2028 $18.66 $28.88 $44.71
2029 $17.36 $29.65 $50.64
2030 $16.41 $30.44 $56.47
09

PFE insider trading

PFE insider trading

Bought
$3.0M
3 open-market purchases
Sold
$135K
2 open-market sales
Insiders filing
9
over the last 18 months
Average trade
$619K
buys and sales together

Month by month

Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26Nov '26

Net insider buying: Insiders bought $3.0M on the open market and sold $135K.

Insider transactions in PFE
Date Insider Type Shares Value
Aug 12, 2026
Albert Bourla
Chief Executive Officer
Buy 38.0K $1.0M
Aug 5, 2026
Jennifer B. Damico
Officer
Sell 3.3K $83.3K
Aug 5, 2026
Ronald E Blaylock
Director
Buy 39.2K $998.8K
Aug 5, 2026
Mortimer J. Buckley
Director
Buy 37.6K $960.4K
Jun 9, 2026
Jennifer B. Damico
Officer
Sell 2.0K $51.4K
Mar 3, 2026
Jennifer B. Damico
Officer
Grant 21.7K -
Feb 25, 2026
Christoffel Boshoff
Officer
Grant 13.4K -
Feb 25, 2026
Albert Bourla
Chief Executive Officer
Option 491.6K $16.6M
Feb 25, 2026
Jennifer B. Damico
Officer
Option 17.6K $593.8K
Feb 25, 2026
Lidia Fonseca, PH.D.
Officer
Option 56.9K $1.9M
10

PFE stock forecast: questions people ask

PFE Forecast: Frequently Asked Questions

What is the PFE stock forecast?
The analysts' median 12-month price target is $30.00, which is 9.5% above the price of $27.40, with targets ranging from $25.00 to $37.00 across 28 analysts. The nearest level below the price is the 200-day simple moving average at $27.03, and the nearest level above is the 50-day simple moving average at $28.82. These are analyst forecasts and do not guarantee where the stock will trade.
What is the PFE price target?
The median 12-month analyst target is $30.00, with the lowest target at $25.00 and the highest at $37.00. The consensus rating is Hold, and the price of $27.40 is 8.7% below the median target. The range shows that analysts disagree on how much the stock could rise.
Is PFE a buy or sell today?
Analysts rate the stock Hold on consensus, with 9 of 28 rating it buy or strong buy, 17 rating it hold and 2 rating it sell or strong sell. CleaRank's own rating is Sell, with a score of 40/100 as of November 20, 2026. The stock is 1.38% above its 200-day average but 4.93% below its 50-day average, so the trend reads as mixed.
Why is the P/E of PFE higher than the sector?
The trailing P/E is 39.14, which is 22.7% above the sector median P/E of 31.9. The trailing earnings per share of $0.70 on a GAAP basis is small relative to the price, which lifts the multiple. Price-to-sales of 2.45 is 27.9% below the sector median of 3.4, so the premium comes from earnings rather than revenue.
How has PFE performed over the past year?
Over one year the stock is up 12.30%, and year to date it is up 10.04%. Over the past month it is down 8.21%, and it sits 12.85% below its 52-week high of $31.44. The stock's 52-week range runs from $23.62 to $31.44.
Does PFE pay a dividend?
Yes, the trailing dividend yield is 6.28% on an annual dividend of $1.72 per share. A yield of that size is a key reason income-focused investors follow the stock, although the share price has moved lower in recent weeks.
What does the recent insider activity show for PFE?
Insiders made three open-market purchases worth $3.0M and two sales worth $135K over the last 18 months. Insider sales are often planned in advance or made to cover tax on vesting shares, so the buying is the more telling of the two.

How these figures are computed, and where the data comes from: CleaRank methodology.

Disclaimer: CleaRank.com is a financial data and analytics provider, not a registered investment advisor, broker-dealer, or financial regulatory body. The stock analysis and AI-generated signals presented for PFE are for educational and informational purposes only and do not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. Simulated scenarios and historical performance figures shown are hypothetical and hindsight-based. They do not represent actual trades made by CleaRank or its affiliates. Stock prices can be volatile and are subject to market, economic, and company-specific risks. Market data is provided "as-is" and may be delayed by up to a minute. We do not guarantee the accuracy, completeness, or timeliness of any data. You should never invest money you cannot afford to lose. Past performance does not guarantee future results. Consult a qualified financial advisor before making any investment decisions. Analysis generated on November 22, 2026.